Abstract:Liver fibrosis is a key process in the progression of chronic liver disease to cirrhosis. Currently, early diagnosis and precise staging of liver fibrosis remain great challenges. Extracellular matrix (ECM) molecules expressed specifically during liver fibrosis are ideal targets for bioimaging and detection of liver fibrosis. Here, we report that fluorescent probes based on a nucleic acid aptamer (ZY-1) targeting cellular fibronectin (cFN), a critical ECM molecule significantly accumulating during liver fibrosis, are promising bioimaging agents for the staging of liver fibrosis. In the work, the outstanding binding affinity of ZY-1 to cFN was validated through an in vitro model of human-derived hepatic stellate cells (HSCs). Subsequently, we constructed different ZY-1-based fluorescent probes and explored the real-time imaging performance of these fluorescent probes in CCl 4 -induced mouse models of different liver fibrosis stages. The ZY-1-based fluorescent probes, for the first time, effectively identified and distinguished early-stage liver fibrosis (stage 3 of Ishak 6) from advanced liver fibrosis (stage 5 of Ishak 6). The proof-of-concept study provides compelling evidences that ZY-1-based probes are a promising tool for the early diagnosis and staging of liver fibrosis and paves the way for further development of clinical-related diagnosis strategies for fibrotic diseases of the liver and other organs. Statement of significance Currently, early diagnosis and accurate staging of liver fibrosis continue to present significant challenges. This study demonstrates that fluorescent probes based on the nucleic acid aptamer ZY-1, which targets cellular fibronectin (cFN)—a crucial extracellular matrix (ECM) molecule that significantly accumulates during liver fibrosis—are promising bioimaging agents for staging liver fibrosis. The ZY-1-based fluorescent probes effectively identified and differentiated early-stage liver fibrosis from advanced liver fibrosis. This proof-of-concept study not only provides compelling evidence that ZY-1-based probes show promise for the early diagnosis and staging of liver fibrosis but also paves the way for further investigations into the use of ZY-1 in detecting other diseases associated with cFN.

Discovery of Aptamer Ligands for Hepatic Stellate Cells Using SELEX

Biomarkers of liver fibrosis detecting with electrochemical immunosensor on clinical serum

Peptide-Based siRNA Nanocomplexes Targeting Hepatic Stellate Cells

Highly Selective Targeting of Hepatic Stellate Cells for Liver Fibrosis Treatment Using a d-Enantiomeric Peptide Ligand of Fn14 Identified by Mirror-Image mRNA Display.

Targeted Drug Delivery to Hepatic Stellate Cells for the Treatment of Liver Fibrosis

Screening and application of aptamers as fluorescent biosensors for selective and sensitive detection of hepatocellular carcinoma and in vivo targeted delivery studies

In Silico Design and Validation of High-Affinity RNA Aptamers Targeting Epithelial Cellular Adhesion Molecule Dimers

Lipidation-dimerization Platform Unlocks Treatment Potential of Fibroblast Growth Factor 21 for Non-Alcoholic Steatohepatitis

Functionalized Aptamer with an Antiparallel G-quadruplex: Structural Remodeling, Recognition Mechanism, and Diagnostic Applications Targeting CTGF.

Identification of an aptamer through whole cell-SELEX for targeting high metastatic liver cancers.

Screening and Verification of Ssdna Aptamers Targeting Human Hepatocellular Carcinoma

Albumin-Based Silibinin Nanocrystals Targeting Activated Hepatic Stellate Cells for Liver Fibrosis Therapy.

The Improving Effects on Hepatic Fibrosis of Interferon-Γ Liposomes Targeted to Hepatic Stellate Cells.

Antibody-drug conjugates targeting CD248 inhibits liver fibrosis through specific killing on myofibroblasts

Hepatic stellate cell-targeted chemo-gene therapy for liver fibrosis using fluorinated peptide-lipid hybrid nanoparticles

Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma

Cyclic Arg-Gly-Asp Peptide-Labeled Liposomes for Targeting Drug Therapy of Hepatic Fibrosis in Rats

Subtractive Cell-SELEX Selection of DNA Aptamers Binding Specifically and Selectively to Hepatocellular Carcinoma Cells with High Metastatic Potential.

Cellular fibronectin-targeted fluorescent aptamer probes for early detection and staging of liver fibrosis

Study on the Antifibrotic Effects of Recombinant Shark Hepatical Stimulator Analogue (r-sHSA) in Vitro and in Vivo